Traders Circle

Against expectations, European banks are thriving Many are now ripe for a takeover

SL Green Realty Corp. Announces Common Stock Dividend NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan's largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.25 per share of common stock, which is the equivalent of an annualized dividend of $3.00 per share. The dividend is payable in cash on August 15, 2024 to shareholders of record at the close of business on July 31, 2024. About SL Green Realty Corp. SL Green Realty Corp., Manhattan's largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of June 30, 2024, SL Green held interests in 55 buildings totaling 31.8 million square feet. This included ownership interests in 28.1 million square feet of Manhattan buildings and 2.8 million ...Full story available on Benzinga.com

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company’s vulnerability to a takeover. Multiple buyout firms are reportedly evaluating Hamburg-based Evotec as a potential acquisition target, initiating early discussions with advisers to assess the company’s drug pipeline and strategic value. Evotec’s shares surged. The spike follows a year-to-date decline of over 60%, with the stock recently hitting its lowest since March 2017. The drop came after Intron Health analysts downgraded the stock from “buy” to “sell.” Bloomberg

What will humans do if technology solves everything? Welcome to a high-tech utopia

Heard on the Street's Stock-Picking Contest Read about our columnists’ favorite and least-favorite stocks and see how they have performed.

3 Tech Industries to Find Penny Stocks In Here are 3 tech industries to find penny stocks in The post 3 Tech Industries to Find Penny Stocks In appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Q&A: How Cliffwater Overcame the Hurdles to RIAs Investing in Private Credit The alternative investment manager was among the first to launch an interval fund in 2019, with a focus on private credit.

Clean Vision Corp (OTC: CLNV): Overcoming the Plastic Waste Crisis Clean Vision Corporation (OTC: CLNV) has experienced several interesting developments recently, but it hasn’t noticeably influenced the market with any substantial gains. Nonetheless, we believe it’s worth providing an update on the company given it’s been a few months since our last mention. In today’s discussion, we’ll explore a variety of updates and their significance, […] The post Clean Vision Corp (OTC: CLNV): Overcoming the Plastic Waste Crisis appeared first on Micro Cap Daily.

Beam Therapeutics Begins Dosing in Phase I/II AATD Study Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo base editing therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD). The open-label, dose-escalation study will investigate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302 for the given indication. The study is designed to identify the optimal dosage of BEAM-302. AATD is an inherited genetic disorder that can cause early onset of emphysema and liver disease. Currently, there are no curative treatments approved for AATD. BEAM received clearance for its clinical trial authorization application from the United Kingdom Medicines and Healthcare Products Regulatory Agency for BEAM-302 in March 2024. Shares of Beam Therapeutics have declined 8.7% year to date compared with the industry's decrease of 4.6%. Image Source: Zacks Investment Research BEAM is also developing another pipeline candidate in its genetic disease portfolio, BEAM-301. The company is looking to initiate ...Full story available on Benzinga.com

As markets soar, should investors look beyond America? The country’s stocks are extremely expensive